osteoporosis
Conditions
Interventions
romosozumab plus active vitamin D group
romosozumab + denosumab plus active vitamin D group
Sponsors
Shinshu University School of Medicine Dept. of Orthopaedic Surgery
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1:All osteoporosis patients over 20 years old or older (but does not correspond to the following exclusion criteria)3 2: Patients who have already received Denosumab (60 mg once every 6 months) for 2 years before the start of the study and have a YAM value of 70% or more or a bone density value of less than -2.5 SD 3:Patients who agree with this study
Exclusion criteria
Exclusion criteria: 1:Patients who have taken romosozumab or denosumab before 2:Patients who are allergic to romosozumab or denosumab or eldecalcitol 3:Hypocalcemia 4:Pregnant or breast-feeding patients 5:Patients with severe renal function (eGFR 30 ml / min / 1.73 m2) or patients undergoing dialysis 6:Patients at risk of hypercalcemia (patients with renal dysfunction, patients with malignancy, patients with primary hyperparathyroidism) 7:Patients with severe liver dysfunction 8:Patients with urolithiasis and patients with a history of their history
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bone mineral density at 12 months after treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Occurrence of hypocalcemia Occurrence of other adverse events | — |
Countries
Japan
Contacts
Public ContactYukio Nakamura
Shinshu University School of Medicine Dept. of Orthopaedic Surgery
Outcome results
None listed